Abstracts tagged "Cardiovascular disease"

Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Alexis Ogdie¹, Yiding Yu², Kevin Haynes³, Samantha Maliha⁴, Thorvardur Love^5,6, Andrea Troxel⁷, Sean Hennessy⁸, David Margolis⁹, Stephen Kimmel¹⁰, Nehal N. Mehta¹¹, Hyon Choi^12,13 and Joel Gelfand¹⁴, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Brigham and Women's Hospital, Boston, MA, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁶Landspitali University Hospital, Reykjavik, Iceland, ⁷Biostatistics and Epidemiology, University of Pennsylvania., Philadelphia, PA, ⁸Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹⁰Cardiology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹¹National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD, ¹²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA
Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…
Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting
Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Lesley-Anne Bissell¹, Elizabeth Hensor², Sarah L. Mackie², Agata Burska³, Jackie L. Nam², Lukasz Kozera², Helen I. Keen⁴, Edith Villeneuve², Heike Eberl⁵, Helena Donica⁶, Philip G. Conaghan⁷, Jacqueline Andrews², Paul Emery⁸ and Ann W. Morgan², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, ⁴Leeds, Leeds, United Kingdom, ⁵Roche Molecular Diagnostics, Burgess Hill, United Kingdom, ⁶Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, ⁷NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁸Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…
Abstract Number: 1672 • 2013 ACR/ARHP Annual Meeting
Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
Grégory Pugnet¹, Laurent Sailler², Guillaume Moulis³, Jean-Pascal Fournier⁴, Robert Bourrel⁵, Jean-Louis Montastruc⁶ and Maryse lapeyre-Mestre⁶, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Clinical Pharmacology Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ⁴Toulouse University, INSERM UMR 1027, Toulouse, France, ⁵Service Médical, Caisse Nationale de l'Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, ⁶Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: No population-based study has assessed serious cardiovascular events (sCVE) risk factors in Giant Cell Arteritis (GCA). The aim of our study was to identify…
Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting
Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008
Anne M. Kerola¹, Tuomo Nieminen², Lauri J. Virta³, Hannu Kautiainen⁴, Kari Puolakka⁵, Tuomas Kerola⁶, Timo Pohjolainen⁷ and Markku J. Kauppi⁶, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ³Research Department, the Social Insurance Institution, Turku, Finland, ⁴Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁷ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland
Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
Abstract Number: 421 • 2013 ACR/ARHP Annual Meeting
Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact?
Mark J Ponsford¹, Jennifer K. Cooney², Bethany Anthony³, Fflur A. Huws⁴, Lauren Evans¹, Jeanette Thom⁵ and Yasmeen Ahmad¹, ¹Betsi Cadwaladr University Health Board, Peter Maddison Research Centre, Llandudno, United Kingdom, ²School of Sport, Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ⁴Health and Exercise Sciences, Bangor University, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ⁵School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients face a burden of cardiovascular disease (CVD) twice that of the general population. RA patients have reduced physical fitness, a…
Abstract Number: 285 • 2013 ACR/ARHP Annual Meeting
Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
Preethi Mani¹, Kiyoko Uno², Katherine Wolski³, Steven J. Spalding⁴, Stephen J. Nicholls⁵ and M. Elaine Husni⁶, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cardiovascular medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ⁴Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁵Clinical Research Heart & Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, ⁶Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Previous literature supports an increase in cardiovascular (CV) morbidity and mortality in adults with inflammatory joint disease, however it is not known whether children with…
Abstract Number: 2726 • 2013 ACR/ARHP Annual Meeting
A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study
Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Chronic inflammation is believed to be responsible for accelerated atherosclerotic cardiovascular disease (CVD) in patients with SLE. Macrophage migration inhibitory factor (MIF) is a…
Abstract Number: 1674 • 2013 ACR/ARHP Annual Meeting
Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study
P. Deepak Udayakumar¹, Arun K. Chandran¹, Cynthia S. Crowson², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Acute coronary syndrome (ACS) is one of the leading causes of death in the general population. We aimed at assessing the occurrence of ACS…
Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting
Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Stefan Kleinert¹, Margret Breunig², Hans-Peter Tony³, Martin Feuchtenberger⁴, Marc Schmalzing⁵, Christian Kneitz⁶, Stefanie Lehmann⁷, Christiane Angermann^7,8, Georg Ertl⁸ and Stefan Störk⁷, ¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ²Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…
Abstract Number: 401 • 2013 ACR/ARHP Annual Meeting
Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Jonny Hisdal⁴, Tore K. Kvien^5,6, Anne S. Eirheim², Terje R. Pedersen⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: During cardiovascular (CV) risk stratification in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), it can be difficult to distinguish between chest pain…
Abstract Number: 287 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Alessandro C. Lianza¹, Nadia E. Aikawa², Julio C. B. Moraes³, Gabriela N. Leal⁴, Samira S. Morhy⁵, Eloisa Bonfa⁶ and Clovis A. Silva⁷, ¹Radiology, University of São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Radiology Division, University of São Paulo, Sao Paulo, Brazil, ⁵Radiology Unit, University of São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, Sao Paulo, Brazil, ⁷Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Subclinical cardiac involvement was previously described in juvenile idiopathic arthritis (JIA) patients, however there is no data regarding echocardiography and cardiac biomarkers evaluations in…
Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Emire Seyahi¹, Deniz Cebi Olgun², SerdaL Ugurlu¹, Idil Hanci³, Reona Takahashi⁴ and Hasan Yazici¹, ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Radiology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Neurology, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany, ⁴Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…
Abstract Number: 1576 • 2013 ACR/ARHP Annual Meeting
Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Christian Lood¹, Helena Tydén¹, Birgitta Gullstrand², Cecilia Klint³, Christina Wenglén³, Christoffer T. Nielsen⁴, Niels H. H. Heegaard⁵, Andreas Jönsen¹ and Anders A. Bengtsson¹, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³R&D, AnaMar AB, Lund, Sweden, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ⁵Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by increased expression of type I interferons (IFNs). Indoleamine 2,3-dioxygenase (IDO), a type I…
Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Joanna Robson¹, Helen Doll², Ravi Suppiah³, Oliver Flossmann⁴, Lorraine Harper⁵, Peter Hoglund⁶, David Jayne⁷, Alfred Mahr⁸, Kerstin Westman⁹ and Raashid A. Luqmani¹⁰, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Department of Population Health, University of East Anglia, Norwich, United Kingdom, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁶Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, ⁷Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁸Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ⁹Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.